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Abstract
Background: Haemostatic alterations are commonly detected in human and canine cancer patients. Previous
studies have described haemostatic dysfunction in canine patients with haemangiosarcomas and carcinomas, and
haemostasis has been assessed in dogs with various malignant and benign neoplasias. Few studies have addressed
the effect of cancer type and progression of disease on the presence of haemostatic alterations in canine patients.
The objective of the present study was to evaluate haemostatic variables of coagulation and fibrinolysis in a group
of canine cancer patients, and to compare haemostatic changes to the cancer type and progression of disease.
Methods: The study population consisted of 71 dogs with malignant neoplasia presented to the University
Hospital for Companion Animals, Faculty of Life Sciences, University of Copenhagen, Denmark. The study was
designed as a prospective observational study evaluating the haemostatic function in canine cancer patients
stratified according to type of cancer disease and disease progression. The coagulation response was evaluated by
thromboelastrography (TEG), platelet count, activated partial thromboplastin time (aPTT), prothombin time (PT),
fibrinogen and antithrombin (AT); and fibrinolysis by d-dimer and plasminogen.
Results: Hypercoagulability was the most common haemostatic dysfunction found. Non mammary carcinomas had
increased clot strength (TEG G), aPTT and fibrinogen compared to the other groups. When stratifying the patients
according to disease progression dogs with distant metastatic disease exhibited significantly increased fibrinogen,
and d-dimer compared to dogs with local invasive and local non-invasive cancers.
Conclusion: Hypercoagulability was confirmed as the most common haemostatic abnormality in canine cancer
patients and haemostatic dysfunction in canine cancer patients was found related to the cancer type and
progression of disease. Increase in TEG G, aPTT and fibrinogen were observed in non-mammary carcinomas and
were speculated to overall represent a proinflammatory response associated with the disease. Dogs with distant
metastatic disease exhibited increased fibrinogen and d-dimer. Future studies are needed to elucidate the clinical
importance of these results.
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Background
Haemostatic dysfunction is a common finding in human
cancer patients who often present with clinical signs of
venous thromboembolism (VTE), pulmonary throm-
boembolism (PTE) or low grade disseminated
intravascular coagulation (DIC) [1,2]. On average 1.5%
of human cancer patients develop clinical signs of VTE
or PTE, with metastatic disease at the time of diagnosis
being the strongest predictor of VTE. In addition, the
incidence of VTE is found to vary with cancer type
[3,4]. Subclinical findings may include abnormal haemo-
static parameters, i.e. elevation of fibrinogen, fibrin
degradation products (FDP) and thrombocytosis [5]. Ele-
vated fibrinopeptide A and d-dimer levels have been
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tumor burden [6,7].
In dogs, cancer has been associated with PTE, though
the condition is rarely diagnosed ante-mortem [8,9]. As
in humans DIC has been reported in canine cancer
patients with metastasizing mammary carcinoma [10],
patients with acute lymphoblastic leukemia [11] and in
dogs with haemangiosarcomas [12]. Subclinical haemo-
static alterations associated with cancer in canine
patients appear to be common. Madewell et al. [13]
found abnormal coagulation parameters in 83% of
tumor bearing dogs with advanced disease including
decreased and increased fibrinogen level, thrombocyto-
penia, prolongation of activated partial thromboplastin
time (aPTT) and increased FDP. Another, more recent
study, found abnormalities in 67% of 60 female dogs
with mammary carcinoma, with the frequency and like-
lihood increasing for stage III and IV disease [14]. In a
recent study hypercoagulability, thrombocytosis and
increased fibrinogen was the most common finding in a
population of 32 canine carcinoma patients compared to
19 healthy controls, though no association between hae-
mostatic changes and presence of metastatic disease
could be made [15].
Thromboleastography (TEG) is a method to evaluate
whole blood coagulability. Only few studies have been
published in human cancer patients, but in other clinical
settings, hypercoagulability as measured by TEG, has
been found to correlate with thrombotic complications
[16,17]. A study in 78 human cancer patients demon-
strate TEG hypercoagulability in patients with solid
tumors but was unable to correlate TEG parameters to
sub-groups of different cancer types or stages of disease
according to the “tumor-node-metastasis” staging system
[18].
In a previous study, Kristensen et al. [19] found hae-
mostatic dysfunction in 57% of dogs with neoplasia.
TEG analysis demonstrated these patients to be primar-
ily hypercoagulable as in human cancer patients.
Furthermore, patients with malignant tumors had a sig-
nificantly higher degree of haemostatic dysfunctions
compared to patients with benign tumors. In addition,
albeit few, patients with hypocoagulable TEG G all had
metastatic disease. Due to incomplete staging proce-
dures and a low number of patients for each tumor
type, the relationship between haemostatic dysfunction
and cancer tissue type or progression of cancer disease
was not examined.
The objective of the present study was to evaluate
haemostatic variables of coagulation and fibrinolysis in a
group of canine cancer patients and to compare haemo-
static changes to cancer type and progression of disease.
We hypothesized that haemostatic dysfunction in canine
cancer is related to the type and progression of disease
and whether the disease is local, regional or if distant
metastases are present.
Materials and methods
This study was approved by the Small Animal Ethics
and Administrative Committee at the Department of
Small Animal Clinical Sciences, Faculty of Life Sciences,
University of Copenhagen Denmark.
Study population
The study was performed as a prospective observational
study, during a three year period from 2007 to 2010 at
the University Hospital for Companion Animals,
Department of Small Animal Clinical Sciences, Faculty
of Life Sciences, University of Copenhagen. The study
included 71 dogs and the mean age of the patients was
8 years and 3 month, (range 1.5 - 14.6 years). The study
population included 52 females of which 11 were spayed
and 19 males of which 5 were castrated.
The clinical and paraclinical evaluation of the patients
included physical examination, evaluation of palpable
draining lymph nodes by fine needle aspiration cytology,
hematology, complete biochemistry profile, coagulation
and fibrinolysis parameters (aPTT, PT, platelet count,
fibrinogen, antithrombin, d-dimer, plasminogen) and
TEG. Staging procedures as recommended by Withrow
and Vail [20] were attempted for each cancer type and
in addition to the above evaluation consisted of radio-
graphs or CT scan of the thorax and/or ultrasound
examination of the abdomen. Diagnosis was obtained by
histopathology for all tumors except for lymphoma and
mastocytoma where a diagnosis based on cytology was
accepted. Patients were excluded from the study if they
were found to have non-malignant tumors or if they
were diagnosed with concurrent illness unrelated to the
cancer diagnosis that was expected to influence the
data. Patients treated with NSAIDs or steroids within
the last 14 days before they were admitted to the Hospi-
tal were excluded as well. None of the patients had
received chemotherapy prior to inclusion.
To evaluate the influence of cancer type on the hae-
mostatic parameters, the patients were grouped accord-
ing to their cancer type as having either mammary
gland carcinoma (n = 23, carcinoma - mammary), carci-
nomas located at other sites than the mammary gland
(n = 7; carcinoma - other site), osteosarcoma (n = 6),
soft tissue sarcomas (n = 13), mastocytoma (n = 12), or
lymphoma (n = 10).
To evaluate the influence of progression of disease on
the haemostatic parameters, patients were grouped as hav-
ing presence of local disease without invasion ("local non-
invasive"; n = 3), local disease with invasion ("local inva-
sive"; n = 37), regional metastasis (n = 5) or distant meta-
static disease (n = 10). Patients were defined to have local
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had no signs of invasive growth, and patients were
grouped as having local disease with invasion if the tumor
by histopathology had signs of invasive growth. Patients
were grouped as having regional disease if the fine needle
aspiration cytology from draining lymph nodes were
found to contain malignant cells, and to have distant
metastatic disease if cytology and/or imaging showed pre-
sence of distant metastasis. Patients with lymphoma or a
diagnosis by cytology (six dogs with mastocytoma) were
not included in this part of the study.
The distribution of i) patients according to cancer
type, diagnosis by histopathology and progression of dis-
ease, ii) conducted staging procedures and iii) site of
primary and distant sites of cancer for the patients with
distant metastases are shown in details in additional files
1, 2 and 3: [see Additional file 1, 2 and 3].
Blood sampling
Blood was collected during the initial admission to the
Hospital. Whole blood was collected by careful venipunc-
ture using minimal stasis and a 21-G butterfly needle. A
total maximum blood volume of 2% of the body weight
was collected from each patient. Blood for haemostatic
parameters was collected into citrated BD Vacutainers and
was obtained at the same time as blood for routine haema-
tology and biochemistry. After collection, the citrate tubes
were carefully inverted 5 times to ensure mixing of 3.2%
trisodium citrate and blood in a 1:9 ratio. Whole blood for
TEG analysis was stored at room temperature (around 20°
C) until the measurement was performed 30 minutes after
sampling. Blood was centrifuged at 4,000 × g for 120 sec-
onds, and aPTT, PT, fibrinogen and d-dimer analyses
were performed within 30 minutes of blood sampling. In
addition plasma was aliquoted and stored at -80°C.
Hematology and biochemistry
A complete blood count (CBC) consisting of a white
blood cell count, concentration of neutrophils, lympho-
cytes, monocytes, eosinophils,b a s o p h i l s ,e r y t h r o c y t e s ,
evaluation of haemoglobin and haematocrit were evalu-
ated on all patients using EDTA stabilized whole blood
and an automated haematology analyzer (Advia 120, Sie-
mens Healthcare Diagnostics). Biochemical profiles were
measured on serum samples using an automated bio-
chemistry analyzer (Advia 1800 Chemistry System, Sie-
mens Healthcare Diagnostics).
CBC and biochemistry were performed at the Central
Laboratory, Department of Small Animal Clinical
Sciences.
Thromboelastography
The TEG measurements were conducted as previously
described [21]. In brief, recombinant human TF
(Innovin, Dade Behring) was used as activator at a final
concentration of 1:50.000. The TEG analysis was
initiated 30 minutes after the blood was collected. Re-
calcification with 20 μL 280 mmolar CaCl2 was added
to each pre-warmed cup. Finally 20 μL prediluted TF
was mixed with 320 μL canine citrated whole blood and
the premix added to the cup, giving a total volume of
360 μL/cup. The TEG analysis was run for 120 minutes.
T h eT E Gp a r a m e t e r sR ,Ka n dA n g l e( C l o tk i n e t i c s ) ,
MA and G (Clot strength), Ly30 and Ly60 (fibrinolysis)
were evaluated for all patients as previously reported
[19,22]. G was calculated from MA with G = 5,000 ×
MA/(100 - MA) and is a measure of the overall coagu-
lant state as normo-, hyper-, or hypo-coagulant. Patients
were considered to be normocoagulable when the TEG
G value was within the normal range of 3.2-7.2 × 10
3
dyn/cm
2. A TEG G value below the normal range was
considered as hypocoagulable and values above defined
as hypercoagulable [23].
Coagulation tests
All haemostatic tests were performed at the Central
Laboratory employing commercial reagents in a vali-
dated setup with an automated coagulometer (ACLTop
500, Instrumentation Laboratory) as previously
described [24]: aPTT (SynthAFax, Instrumentation
Laboratory); PT (RecombiPlasTin 2G, Instrumentation
Laboratory); d-dimer (D-Dimer Single Tests, NycoCard
READER II, Medinor A/S); fibrinogen (RecombiPlasTin
2G, Instrumentation Laboratory); AT (Liquid Antith-
rombin; Instrumentation Laboratory) and plasminogen
(Plasminogen, Instrumentation Laboratory). A pooled
sample of plasma from ten clinical healthy dogs was
analyzed together with the patient samples and used as
internal control. Platelet count was measured using an
automated haematology analyzer (Advia 120) using
EDTA stabilized whole blood. Normal values for the
clot assay of aPTT, PT, fibrinogen and d-dimer were
based on internal validation and normal values of 30
clinical healthy dogs. Due to technical failures and lost
samples, aPTT was missing for 10 dogs, PT was miss-
ing in two dogs, fibrinogen was missing in two dogs,
AT missing in 16 dogs and plasminogen missing in 15
dogs.
Statistical analysis
Data was tested for normal distribution using Shapiro-
Wilk test for normality. Since values were not normally
distributed, the statistical analysis was carried out as
non-parametric. Kruskal Wallis test was used for com-
parison of numerical values for multiple groups. When
there was overall statistical significance, a Dunn’sP o s t
Test for multiple comparisons was used to compare the
individual groups.
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ware program SAS 9.1 edition (SAS Institute Inc) and
GraphPad Prism 5 (GrapfPad Software). P <0 . 0 5w a s
chosen as a significant level.
Results
An abnormal TEG profile was found in 50 of the 71
dogs investigated (70.4%). Forty-seven dogs (66.2%) were
hypercoagulable, 3 dogs (4.2%) were hypocoagulable and
21 dogs (29.6%) were normocoagulable. The distribution
according to TEG coagulability is displayed in table 1.
In the 50 patients with an abnormal TEG hypercoagul-
ability was the most common abnormality (94%). All
hypocoagulable patients were found to have systemic
cancer disease; one dog had mammary carcinoma (tubu-
lopapillary carcinoma) and distant metastases, one dog
had mammary carcinoma (anaplastic carcinoma) and
metastases to the draining lymph node and one dog had
lymphoma stage V (B-cell origin).
Haemostatic changes according to cancer type
An overall significant difference was found in TEG clot
strength (median G value (P = 0.0406; Figure 1) and
MA (P = 0.0407; data shown in an additional file [see
Additional file 4]) between the cancer types. Patients
with “Carcinomas at other sites” had a significantly
increased TEG G and MA compared to lymphoma
patients (P < 0.05). No significant differences were
found between the different cancer types for the other
TEG parameter (R, K, Angle, LY30, and Ly60; data
shown in an additional file [seeAdditional file 4]).
An overall significant difference between the cancer
types was found for aPTT (P = 0.0093; Figure 1) and
fibrinogen (P = 0.0086; Figure 1). “Carcinomas at other
sites” had a significantly increased aPTT (P < 0.05) and
fibrinogen level (P < 0.05) compared to dogs with mas-
tocytoma and lymphoma. No differences between the
cancer types were found for PT, d-dimer and platelet
count (Figure 1), nor for AT and plasminogen (data
shown in an additional file [see Additional file 4]).
Haemostatic changes according to progression of disease
No statistical significant differences were found between
the disease progression groups for TEG G (Figure 2) or
any other TEG parameters (data shown in an additional
file [see Additional file 5]).
An overall significant difference between the disease
progression groups were found for fibrinogen (P =
0.0041) and d-dimer (P = 0.0076) (Figure 2).
Patients with distant metastases were found to have a
significant higher fibrinogen level than patients with
local invasive (P < 0.05) and local non-invasive cancer
(P < 0.01), and patients with distant metastases had a
significantly elevated d-dimer compared to patients with
local invasive disease (P < 0.05).
No difference between the disease progression groups
were found for aPTT, PT, or platelet count (Figure 2) or
for AT and plasminogen (data shown in an additional
file: [see Additional file 5]).
Discussion
In the current study, carcinomas located at other sites
than the mammary glands were found to have an
increased TEG G value, aPTT and fibrinogen compared to
the other evaluated cancer types. In addition patients with
distant metastatic disease were found to have elevated
levels of fibrinogen and d-dimer compared to patients
with local invasive and local non-invasive disease.
All the investigated cancer types in this study exhib-
ited elevated median TEG G values and tended to be
hypercoagulable, though the highest TEG G levels were
seen in the group of patients with non mammary carci-
nomas ("carcinomas at other sites”). These patients were
also found to have the highest median aPTT and fibri-
nogen level, even significantly when compared to the
groups with mastocytomas and lymphomas.
Table 1 Distribution of patients based on thromboelastography determined coagulability (G), cancer type and disease
progression group
TEG G N(ct) CM COS OS STS M L N(dp) DM RM LI LNI
Normo
(3.2-7.2)
29.6%
(21)
21.7%
(5)
0%
(0)
33.3%
(2)
46.2%
(6)
41.7%
(5)
30%
(3)
29.1%
(16)
20%
(2)
0%
(0)
29.7%
(11)
100%
(3)
Hyper
(> 7.2)
66.2%
(47)
69.6%
(16)
100%
(7)
66.7%
(4)
53.8%
(7)
58.3%
(7)
60%
(6)
67.3%
(37)
70%
(7)
80%
(4)
70.3%
(26)
0%
(0)
Hypo
(< 3.2)
4.2%
(3)
8.7%
(2)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
10%
(1)
3.6%
(2)
10%
(1)
20%
(1)
0%
(0)
0%
(0)
N 71 23 7 6 13 12 10 55 10 5 37 3
In percentage is the proportion of patients for the given cancer type or disease progression group.
TEG G = Coagulability measured by TEG G; N(ct) = Percentage and number of patients (in total) evaluated by cancer type; CM = Carcinoma located in the
mammary gland; COS = Carcinoma located at other sites than the mammary gland; OS = Osteosarcoma; STS = Soft tissue sarcoma; M = Mastocytoma; L =
Lymphoma; N(dp) = Percentage and number of patients (in total) evaluated by disease progression group; DM = Distant metastases; RM = Regional metastases;
LI = Local invasive; LNI = Local non-invasive.
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tively correlate with TEG G in addition to platelet count
[15,22,25]. We speculate, that the fibrinogen level in
combination with the slightly elevated median aPTT
and the haemostatic changes (elevated TEG G), likely is
the net result of a systemic inflammatory reaction seen
in these patients, in part mediated through proinflam-
matory changes in and around the cancer cells [26-28].
The patients with distant metastases were even found
to have significantly increased fibrinogen levels com-
pared to patients with local invasive and local non-inva-
sive cancers, which is in accordance with findings made
by other authors, who related hyperfibrinogenemia to
stage of disease in canine mammary carcinoma patients
[14]. Also, increased fibrinogen levels have been asso-
ciated with progression and extend of cancer disease in
human patients [1]. As previously mentioned the ele-
vated fibrinogen seen in patients with metastatic disease
indicates that systemic inflammation is associated with
progression of the cancer disease.
The patients with distant metastatic disease had a sig-
nificantly elevated d-dimer level and thereby more pro-
nounced activation of the coagulation and fibrinolytic
systems than patients with local invasive disease. Ele-
vated d-dimer levels are found in both human and
canine patients with VTE but also in other conditions
such as wound healing, DIC and haemorrhagic condi-
tions [29,30]. None of the patients in this study had
undergone surgery before blood sampling, but two of
the patients with distant metastatic disease were diag-
nosed with DIC. None of the patients were diagnosed
with VTE, though the presence of a thromboembolic
event could have been missed. Due to decreased liver
clearance, increased d-dimer can be found in patients
with cirrhotic liver disease and two of the patients with
distant metastasis had elevated liver enzymes. Anyway,
it is unlikely that these patients, without clinical signs of
liver involvement, were affected by their liver disease to
an extend being the sole reason for alterations of their
haemostatic and fibrinolytic profiles
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Figure 1 Thromboelastography G, activated partial thromboplastin time, prothrombin time, fibrinogen, d-dimer and platelet count
grouped by cancer type. The TEG parameter G represents the clot strength. The short solid lines represent the median value for each cancer
type. The dotted lines represent the reference interval (G: 3.2-7.2 x10
3 dyn/cm
2; aPTT: 7 - 11.9 sec; PT: < 8.5 sec; fibrinogen: 1-4 g/L; d-dimer: <
0.5 mg/L; platelet count: 200-500 10
9/L). Overall significance is evaluated by Kruskal Wallis test and indicated by brackets. (NS): non-significant
(Kruskal Wallis). Dunn’s Post Test was used to test for statistical significance between groups.┌──┐ indicates statistical significance between the
groups at each end of the bar. * = Dunn’s Post Test: P < 0.05.
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be hypocoagulable on TEG. Two of the dogs had mam-
mary carcinomas and metastases to either the regional
lymph node or distant sites, while the third dog had
lymphoma stage V. These findings are in accordance
with previous findings by Kristensen et al. [19], where
hypocoagulable dogs by TEG all had metastatic disease
or lymphoma. The limited number of hypocoagulable
dogs included in this study is not sufficient to state
whether all hypocoagulable cancer patients have sys-
temic cancer disease.
More than 90% of human cancer patients have subcli-
nical haemostatic abnormalities with the majority of
patients showing hypercoagulability associated with ele-
vated fibrinogen levels, thrombocytosis, elevated levels
of clotting factors V, VIII, IX and X and elevated levels
of FDP, in addition to reduced levels of coagulation
inhibitors (AT, Protein C and Protein S) and increased
levels of plasminogen activator inhibitor-1 [1,5,31]. Simi-
larly, the majority of canine cancer patients have been
found to have subclinical haemostatic alterations as
were found in this study [13-15,19].
Haemostatic dysfunction and hypercoagulability in
cancer patients is complex with a multifactorial aetiol-
ogy that includes expression of procoagulant molecules
such as tissue factor on the surface of malignant cells,
release of fibrinolytic peptides, inhibition of endogenous
anticoagulation, release of cytokines by cancer cells, and
interaction with host cells including endothelial cells
and blood leukocytes [28,32]. Increased presence of acti-
vated platelets and release of platelet micro vesicles has
also been related to hypercoagulability in cancer [33-35].
All these mechanisms additionally support cancer cell
growth and metastasis.
In humans, hypercoagulability measured by TEG has
been associated with increased risk of thromboembolism
especially in post operative patients [16] but has not yet
been identified as a predictor of VTE in cancer patients.
In order to verify the current findings, further studies
including more patients of each cancer type and disease
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Figure 2 Thromboelastography G, activated partial thromboplastin time, prothrombin time, fibrinogen, d-dimer and platelet count
grouped by progression of disease. The TEG parameter G represents the clot strength. The short solid lines represent the median value for
each disease progression group. The dotted lines represent the reference interval (G: 3.2-7.2 x10
3 dyn/cm
2; aPTT: 7 - 11.9 sec; PT: < 8.5 sec;
fibrinogen: 1-4 g/L; d-dimer: < 0.5 mg/L; platelet count: 200-500 10
9/L). Overall significance is evaluated by Kruskal Wallis test and indicated by
brackets. (NS): non-significant (Kruskal Wallis). Dunn’s Post Test was used to test for statistical significance between groups. ┌──┐ indicates
statistical significance between the groups at each end of the bar. * = Dunn’s Post Test: P < 0.05. ** = Dunn’s Post test: P < 0.01.
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the clinical impact of the hypercoagulable state in can-
cer patients and its possible association with VTE in
both humans and dogs should be pursued. It appears
that human and canine cancer patients develop similar
haemostatic alterations, though thromboembolic compli-
cations are seldom recognized in dogs. The similarities
of the haemostatic alterations, supports cancer bearing
pet dogs as a valuable clinical translational animal
model for studying the bidirectional link between hae-
mostasis and cancer in humans.
Conclusions
Haemostatic alterations were related to disease progres-
sion and type of cancer in this population of canine can-
cer patients. Hypercoagulability was confirmed as the
most common haemostatic abnormality in canine cancer
patients and haemostatic dysfunction in canine cancer
patients was found related to cancer type and progres-
sion of disease. Increase in TEG G, aPTT and fibrinogen
were observed in non-mammary carcinomas and were
speculated to overall represent a proinflammatory
response associated with the disease. Dogs with distant
metastatic disease exhibited increased fibrinogen, and d-
dimer. Future studies are needed to elucidate the clinical
importance of these results.
Additional material
Additional file 1: The distribution of patients according to cancer
type, diagnosis by histopathology and progression of disease. The
table displays the distribution of patients according to cancer type,
subdivided by the diagnosis by histopathology, the site of cancer,
progression of disease, mean age of the patients, and their sex.
Additional file 2: The distribution of patients according to cancer
type, diagnose by histopathology and staging procedures
performed. The table displays the distribution of patients according to
cancer type, subdivided by the diagnosis by histopathology and the
staging procedures performed.
Additional file 3: Size and site of primary and metastatic cancer for
patients with distant metastases. A list of the included patients with
distant metastatic disease describing their site of primary and secondary
cancer and paraclinical alteration regarding liver and kidney values
evaluated by biochemistry.
Additional file 4: TEG variables, haemostatic and fibrinolytic
variables according to cancer type. Graphic distribution of the TEG
values R, K, Angle, Ly30, Ly60, and MA and antithrombin (AT),
plasminogen, and haematocrit according to cancer type.
Additional file 5: TEG variables, haemostatic and fibrinolytic
variables according to disease progression group. Graphic
distribution of the TEG values R, K, Angle, Ly30, Ly60, and MA and
antithrombin (AT), plasminogen, and haematocrit according to disease
progression group.
Abbreviations
aPTT: activated partial thromboplastin time; AT: antithrombin; CBC: complete
blood count; CT scan: × ray computed tomography; DIC: disseminated
intravascular coagulation; EDTA: Ethylenediaminetetraacetic acid; FDP: fibrin
(ogen) degradation products; NSAIDs: Non-steroidal anti-inflammatory drugs;
PT: prothrombin time; PTE: pulmonary thromboembolism; TEG:
Thromboelastography; VTE: venous thromboembolism.
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